25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

CLVLF (Clinuvel) Stock Analysis
Buy, Hold or Sell?

Let's analyze Clinuvel together

I guess you are interested in Clinuvel Pharmaceuticals Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Clinuvel’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Clinuvel’s Price Targets

I'm going to help you getting a better view of Clinuvel Pharmaceuticals Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.

1. Quick Overview

1.1. Quick analysis of Clinuvel (30 sec.)










1.2. What can you expect buying and holding a share of Clinuvel? (30 sec.)

How much money do you get?

How much money do you get?
$0.13
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
$3.11
Expected worth in 1 year
$5.20
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
$2.22
Return On Investment
29.9%

For what price can you sell your share?

Current Price per Share
$7.43
Expected price per share
$6.81 - $8.6
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Clinuvel (5 min.)




Live pricePrice per Share (EOD)
$7.43
Intrinsic Value Per Share
$3.15 - $10.57
Total Value Per Share
$6.27 - $13.69

2.2. Growth of Clinuvel (5 min.)




Is Clinuvel growing?

Current yearPrevious yearGrowGrow %
How rich?$156.9m$132.2m$24.6m15.7%

How much money is Clinuvel making?

Current yearPrevious yearGrowGrow %
Making money$23.5m$23.2m$349.3k1.5%
Net Profit Margin38.1%40.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Clinuvel (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#267 / 849

Most Revenue
#125 / 849

Most Profit
#61 / 849
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Clinuvel?

Welcome investor! Clinuvel's management wants to use your money to grow the business. In return you get a share of Clinuvel.

First you should know what it really means to hold a share of Clinuvel. And how you can make/lose money.

Speculation

The Price per Share of Clinuvel is $7.43. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Clinuvel.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Clinuvel, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $3.11. Based on the TTM, the Book Value Change Per Share is $0.52 per quarter. Based on the YOY, the Book Value Change Per Share is $0.52 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.03 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Clinuvel.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.476.3%0.476.3%0.466.1%0.445.9%0.385.1%0.253.4%
Usd Book Value Change Per Share0.527.0%0.527.0%0.527.0%0.516.9%0.435.8%0.304.0%
Usd Dividend Per Share0.030.4%0.030.4%0.030.4%0.030.4%0.020.3%0.020.2%
Usd Total Gains Per Share0.557.5%0.557.5%0.557.5%0.547.3%0.466.1%0.314.2%
Usd Price Per Share7.22-7.22-10.10-5.77-7.76-9.61-
Price to Earnings Ratio15.43-15.43-22.19-12.54-21.15-32.59-
Price-to-Total Gains Ratio13.02-13.02-18.24-15.63-32.60-49.53-
Price to Book Ratio2.32-2.32-3.90-2.07-4.66-11.82-
Price-to-Total Gains Ratio13.02-13.02-18.24-15.63-32.60-49.53-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share7.43
Number of shares134
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.030.02
Usd Book Value Change Per Share0.520.43
Usd Total Gains Per Share0.550.46
Gains per Quarter (134 shares)74.3161.19
Gains per Year (134 shares)297.24244.77
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
11728028713232235
23556058426464480
35284088139696725
4691120117851928970
587139914756411601215
6104167917727713911460
7122195920699016231705
81392239236610318551950
91562519266311620872195
101742799296012923192440

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%9.016.00.036.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%16.09.00.064.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%9.00.016.036.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%16.09.00.064.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Clinuvel Pharmaceuticals Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.5220.5220%0.522+0%0.511+2%0.433+21%0.297+76%
Book Value Per Share--3.1153.1150%2.592+20%2.592+20%2.123+47%1.338+133%
Current Ratio--9.6649.6640%8.808+10%8.636+12%9.592+1%10.152-5%
Debt To Asset Ratio--0.1140.1140%0.122-6%0.129-11%0.121-6%0.109+4%
Debt To Equity Ratio--0.1280.1280%0.138-7%0.148-13%0.138-7%0.123+5%
Dividend Per Share--0.0320.0320%0.032+3%0.030+9%0.024+35%0.017+87%
Enterprise Value--489606390.130489606390.1300%616860598.561-21%553233494.345-12%750660947.196-35%655824102.584-25%
Eps--0.4680.4680%0.455+3%0.436+7%0.377+24%0.254+84%
Ev To Ebitda Ratio--13.13713.1370%16.822-22%14.980-12%30.772-57%44.432-70%
Ev To Sales Ratio--7.9087.9080%10.736-26%9.322-15%18.343-57%31.074-75%
Free Cash Flow Per Share--0.5280.5280%0.402+31%0.306+73%0.180+193%0.134+295%
Free Cash Flow To Equity Per Share--0.4900.4900%0.356+37%0.268+82%0.150+226%0.125+291%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%0.931+7%
Intrinsic Value_10Y_max--10.575----------
Intrinsic Value_10Y_min--3.152----------
Intrinsic Value_1Y_max--0.469----------
Intrinsic Value_1Y_min--0.181----------
Intrinsic Value_3Y_max--1.860----------
Intrinsic Value_3Y_min--0.665----------
Intrinsic Value_5Y_max--3.793----------
Intrinsic Value_5Y_min--1.276----------
Market Cap372991498.200+2%363740365.440363740365.4400%515369801.300-29%293036722.247+24%395429978.998-8%485915256.904-25%
Net Profit Margin--0.3810.3810%0.404-6%0.392-3%0.401-5%0.354+8%
Operating Margin--0.5900.5900%0.625-6%0.612-4%0.5920%0.416+42%
Operating Ratio--0.5190.5190%0.443+17%0.466+11%0.453+15%0.618-16%
Pb Ratio2.386+3%2.3182.3180%3.896-40%2.071+12%4.656-50%11.824-80%
Pe Ratio15.881+3%15.43215.4320%22.194-30%12.542+23%21.155-27%32.586-53%
Price Per Share7.430+3%7.2207.2200%10.100-29%5.773+25%7.759-7%9.612-25%
Price To Free Cash Flow Ratio14.081+3%13.68313.6830%25.127-46%12.937+6%-386.735+2926%-327.263+2492%
Price To Total Gains Ratio13.398+3%13.02013.0200%18.242-29%15.631-17%32.603-60%49.533-74%
Quick Ratio--9.2459.2450%14.230-35%11.904-22%13.834-33%13.247-30%
Return On Assets--0.1330.1330%0.154-14%0.148-10%0.164-19%0.172-22%
Return On Equity--0.1500.1500%0.176-14%0.171-12%0.186-19%0.191-21%
Total Gains Per Share--0.5550.5550%0.554+0%0.541+2%0.457+21%0.314+76%
Usd Book Value--156910900.702156910900.7020%132282206.086+19%132155586.522+19%108523668.796+45%68176291.912+130%
Usd Book Value Change Per Share--0.5220.5220%0.522+0%0.511+2%0.433+21%0.297+76%
Usd Book Value Per Share--3.1153.1150%2.592+20%2.592+20%2.123+47%1.338+133%
Usd Dividend Per Share--0.0320.0320%0.032+3%0.030+9%0.024+35%0.017+87%
Usd Enterprise Value--489606390.130489606390.1300%616860598.561-21%553233494.345-12%750660947.196-35%655824102.584-25%
Usd Eps--0.4680.4680%0.455+3%0.436+7%0.377+24%0.254+84%
Usd Free Cash Flow--26583258.08526583258.0850%20510847.817+30%15474855.350+72%9116961.616+192%6750616.204+294%
Usd Free Cash Flow Per Share--0.5280.5280%0.402+31%0.306+73%0.180+193%0.134+295%
Usd Free Cash Flow To Equity Per Share--0.4900.4900%0.356+37%0.268+82%0.150+226%0.125+291%
Usd Market Cap372991498.200+2%363740365.440363740365.4400%515369801.300-29%293036722.247+24%395429978.998-8%485915256.904-25%
Usd Price Per Share7.430+3%7.2207.2200%10.100-29%5.773+25%7.759-7%9.612-25%
Usd Profit--23570012.72923570012.7290%23220651.524+2%22244199.820+6%19289986.600+22%13035418.815+81%
Usd Revenue--61913448.61261913448.6120%57456985.493+8%56801534.971+9%48942623.948+27%31771209.775+95%
Usd Total Gains Per Share--0.5550.5550%0.554+0%0.541+2%0.457+21%0.314+76%
 EOD+4 -4MRQTTM+0 -0YOY+25 -143Y+24 -155Y+24 -1510Y+25 -15

3.3 Fundamental Score

Let's check the fundamental score of Clinuvel Pharmaceuticals Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.881
Price to Book Ratio (EOD)Between0-12.386
Net Profit Margin (MRQ)Greater than00.381
Operating Margin (MRQ)Greater than00.590
Quick Ratio (MRQ)Greater than19.245
Current Ratio (MRQ)Greater than19.664
Debt to Asset Ratio (MRQ)Less than10.114
Debt to Equity Ratio (MRQ)Less than10.128
Return on Equity (MRQ)Greater than0.150.150
Return on Assets (MRQ)Greater than0.050.133
Total8/10 (80.0%)

3.4 Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.430
Total0/1 (0.0%)

4. In-depth Analysis

4.1 About Clinuvel Pharmaceuticals Ltd

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Fundamental data was last updated by Penke on 2025-10-15 19:46:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Clinuvel earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Net Profit Margin of 38.1%Β means thatΒ $0.38 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 38.1%. The company is making a huge profit. +2
  • The TTM is 38.1%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ38.1%TTM38.1%0.0%
TTM38.1%YOY40.4%-2.3%
TTM38.1%5Y40.1%-2.0%
5Y40.1%10Y35.4%+4.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ38.1%-77.3%+115.4%
TTM38.1%-167.4%+205.5%
YOY40.4%-186.4%+226.8%
3Y39.2%-263.9%+303.1%
5Y40.1%-345.5%+385.6%
10Y35.4%-477.5%+512.9%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Clinuvel is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 13.3% Return on Assets means thatΒ Clinuvel generatedΒ $0.13 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 13.3%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 13.3%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ13.3%TTM13.3%0.0%
TTM13.3%YOY15.4%-2.1%
TTM13.3%5Y16.4%-3.1%
5Y16.4%10Y17.2%-0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.3%-12.0%+25.3%
TTM13.3%-11.9%+25.2%
YOY15.4%-11.0%+26.4%
3Y14.8%-12.0%+26.8%
5Y16.4%-11.7%+28.1%
10Y17.2%-13.8%+31.0%
4.3.1.3. Return on Equity

Shows how efficient Clinuvel is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • 15.0% Return on Equity means Clinuvel generated $0.15Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 15.0%. Using its investors money, the company is efficient in making profit. +1
  • The TTM is 15.0%. Using its investors money, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ15.0%TTM15.0%0.0%
TTM15.0%YOY17.6%-2.5%
TTM15.0%5Y18.6%-3.5%
5Y18.6%10Y19.1%-0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.0%-14.2%+29.2%
TTM15.0%-14.8%+29.8%
YOY17.6%-15.0%+32.6%
3Y17.1%-16.6%+33.7%
5Y18.6%-16.9%+35.5%
10Y19.1%-19.5%+38.6%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Clinuvel Pharmaceuticals Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Clinuvel is operatingΒ .

  • Measures how much profit Clinuvel makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • An Operating Margin of 59.0%Β means the company generated $0.59 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 59.0%. The company is operating very efficient. +2
  • The TTM is 59.0%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ59.0%TTM59.0%0.0%
TTM59.0%YOY62.5%-3.6%
TTM59.0%5Y59.2%-0.2%
5Y59.2%10Y41.6%+17.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ59.0%-154.1%+213.1%
TTM59.0%-266.1%+325.1%
YOY62.5%-246.9%+309.4%
3Y61.2%-247.4%+308.6%
5Y59.2%-338.0%+397.2%
10Y41.6%-498.1%+539.7%
4.3.2.2. Operating Ratio

Measures how efficient Clinuvel is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 0.52 means that the operating costs are $0.52 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.519. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.519. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.519TTM0.5190.000
TTM0.519YOY0.443+0.076
TTM0.5195Y0.453+0.066
5Y0.45310Y0.618-0.165
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5191.873-1.354
TTM0.5192.793-2.274
YOY0.4432.820-2.377
3Y0.4663.575-3.109
5Y0.4534.664-4.211
10Y0.6186.406-5.788
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Clinuvel Pharmaceuticals Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Clinuvel is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 9.66Β means the company has $9.66 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 9.664. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.664. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.664TTM9.6640.000
TTM9.664YOY8.808+0.856
TTM9.6645Y9.592+0.072
5Y9.59210Y10.152-0.561
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.6643.414+6.250
TTM9.6643.605+6.059
YOY8.8084.036+4.772
3Y8.6364.431+4.205
5Y9.5925.716+3.876
10Y10.1526.128+4.024
4.4.3.2. Quick Ratio

Measures if Clinuvel is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Quick Ratio of 9.25Β means the company can pay off $9.25 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 9.245. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.245. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.245TTM9.2450.000
TTM9.245YOY14.230-4.985
TTM9.2455Y13.834-4.589
5Y13.83410Y13.247+0.587
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.2452.910+6.335
TTM9.2453.135+6.110
YOY14.2303.825+10.405
3Y11.9044.359+7.545
5Y13.8345.692+8.142
10Y13.2476.524+6.723
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Clinuvel Pharmaceuticals Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of ClinuvelΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Clinuvel to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11Β means that Clinuvel assets areΒ financed with 11.4% credit (debt) and the remaining percentage (100% - 11.4%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.114. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.114. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.114TTM0.1140.000
TTM0.114YOY0.122-0.008
TTM0.1145Y0.121-0.007
5Y0.12110Y0.109+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1140.342-0.228
TTM0.1140.360-0.246
YOY0.1220.331-0.209
3Y0.1290.344-0.215
5Y0.1210.348-0.227
10Y0.1090.378-0.269
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Clinuvel is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 12.8% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The MRQ is 0.128. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.128. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.128TTM0.1280.000
TTM0.128YOY0.138-0.010
TTM0.1285Y0.138-0.009
5Y0.13810Y0.123+0.015
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1280.399-0.271
TTM0.1280.439-0.311
YOY0.1380.429-0.291
3Y0.1480.471-0.323
5Y0.1380.471-0.333
10Y0.1230.518-0.395
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Clinuvel generates.

  • Above 15 is considered overpriced butΒ always compareΒ Clinuvel to theΒ Biotechnology industry mean.
  • A PE ratio of 15.43 means the investor is paying $15.43Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 15.881. Based on the earnings, the company is fair priced.
  • The MRQ is 15.432. Based on the earnings, the company is fair priced.
  • The TTM is 15.432. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD15.881MRQ15.432+0.449
MRQ15.432TTM15.4320.000
TTM15.432YOY22.194-6.762
TTM15.4325Y21.155-5.722
5Y21.15510Y32.586-11.431
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.881-2.903+18.784
MRQ15.432-2.296+17.728
TTM15.432-2.701+18.133
YOY22.194-3.622+25.816
3Y12.542-3.843+16.385
5Y21.155-6.007+27.162
10Y32.586-6.985+39.571
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 14.081. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 13.683. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 13.683. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD14.081MRQ13.683+0.398
MRQ13.683TTM13.6830.000
TTM13.683YOY25.127-11.444
TTM13.6835Y-386.735+400.418
5Y-386.73510Y-327.263-59.473
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD14.081-3.599+17.680
MRQ13.683-2.919+16.602
TTM13.683-3.869+17.552
YOY25.127-4.296+29.423
3Y12.937-5.305+18.242
5Y-386.735-8.442-378.293
10Y-327.263-9.887-317.376
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Clinuvel is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 2.32 means the investor is paying $2.32Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Clinuvel Pharmaceuticals Ltd:

  • The EOD is 2.386. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.318. Based on the equity, the company is underpriced. +1
  • The TTM is 2.318. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.386MRQ2.318+0.067
MRQ2.318TTM2.3180.000
TTM2.318YOY3.896-1.578
TTM2.3185Y4.656-2.338
5Y4.65610Y11.824-7.168
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3862.495-0.109
MRQ2.3182.062+0.256
TTM2.3182.248+0.070
YOY3.8962.465+1.431
3Y2.0712.704-0.633
5Y4.6563.831+0.825
10Y11.8244.581+7.243
4.6.2. Total Gains per Share

2.4. Latest News of Clinuvel Pharmaceuticals Ltd

Does Clinuvel Pharmaceuticals Ltd still have the same value as the quarterly reports suggest? Recent changes may be an indication that the value of the company is changing. Read the news from Clinuvel Pharmaceuticals Ltd to keep up to date. Note: the news is often already included in the price.

DateTitleRead
2025-10-08
21:40
Top Three High Growth Tech Stocks in AustraliaRead
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets271,750
Total Liabilities30,941
Total Stockholder Equity240,809
 As reported
Total Liabilities 30,941
Total Stockholder Equity+ 240,809
Total Assets = 271,750

Assets

Total Assets271,750
Total Current Assets262,969
Long-term Assets8,781
Total Current Assets
Cash And Cash Equivalents 224,106
Net Receivables 27,461
Inventory 8,821
Other Current Assets 2,581
Total Current Assets  (as reported)262,969
Total Current Assets  (calculated)262,969
+/-0
Long-term Assets
Property Plant Equipment 7,127
Long Term Investments 213
Intangible Assets 185
Long-term Assets  (as reported)8,781
Long-term Assets  (calculated)7,525
+/- 1,255

Liabilities & Shareholders' Equity

Total Current Liabilities27,211
Long-term Liabilities3,731
Total Stockholder Equity240,809
Total Current Liabilities
Short-term Debt 431
Accounts payable 2,551
Other Current Liabilities 24,229
Total Current Liabilities  (as reported)27,211
Total Current Liabilities  (calculated)27,211
+/-0
Long-term Liabilities
Capital Lease Obligations 529
Long-term Liabilities  (as reported)3,731
Long-term Liabilities  (calculated)529
+/- 3,202
Total Stockholder Equity
Common Stock169,281
Retained Earnings 63,632
Accumulated Other Comprehensive Income 7,896
Total Stockholder Equity (as reported)240,809
Total Stockholder Equity (calculated)240,809
+/-0
Other
Capital Stock169,281
Cash and Short Term Investments 224,106
Common Stock Shares Outstanding 50,380
Liabilities and Stockholders Equity 271,750
Net Debt -223,577
Net Invested Capital 240,809
Net Working Capital 235,758
Property Plant and Equipment Gross 10,952
Short Long Term Debt Total 529



6.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2025-06-302024-06-302023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-30
> Total Assets 
15,441
13,769
10,520
8,066
10,247
10,056
17,071
67,825
54,971
41,614
29,507
20,165
15,995
15,815
17,154
13,644
20,138
28,607
42,905
62,345
81,542
108,568
143,950
193,714
231,124
271,750
271,750231,124193,714143,950108,56881,54262,34542,90528,60720,13813,64417,15415,81515,99520,16529,50741,61454,97167,82517,07110,05610,2478,06610,52013,76915,441
   > Total Current Assets 
7,995
7,028
4,483
2,748
5,682
5,246
13,917
65,317
53,120
40,594
29,158
19,932
15,807
15,668
17,039
13,575
19,974
28,470
42,269
61,153
75,156
102,848
140,583
189,618
222,064
262,969
262,969222,064189,618140,583102,84875,15661,15342,26928,47019,97413,57517,03915,66815,80719,93229,15840,59453,12065,31713,9175,2465,6822,7484,4837,0287,995
       Cash And Cash Equivalents 
7,927
6,981
4,414
2,612
5,480
4,763
8,606
33,842
25,752
21,711
19,415
12,178
12,719
12,569
14,626
10,572
13,845
23,752
36,198
54,269
66,747
82,691
121,509
156,814
183,868
224,106
224,106183,868156,814121,50982,69166,74754,26936,19823,75213,84510,57214,62612,56912,71912,17819,41521,71125,75233,8428,6064,7635,4802,6124,4146,9817,927
       Short-term Investments 
0
0
0
0
0
0
2,024
28,512
25,048
16,043
7,588
5,321
454
0
0
0
0
0
0
28,525
41,095
45,550
94,100
132,946
148,668
0
0148,668132,94694,10045,55041,09528,5250000004545,3217,58816,04325,04828,5122,024000000
       Net Receivables 
57
35
30
31
78
137
233
241
616
212
363
974
1,007
1,743
1,585
1,960
4,824
3,239
5,090
4,156
6,350
16,089
16,202
22,215
26,238
27,461
27,46126,23822,21516,20216,0896,3504,1565,0903,2394,8241,9601,5851,7431,0079743632126162412331377831303557
       Other Current Assets 
10
13
39
106
124
314
2,474
2,722
1,703
2,628
1,791
1,460
1,627
1,357
828
205
223
510
339
989
772
882
1,039
1,070
1,330
2,581
2,5811,3301,0701,0398827729893395102232058281,3571,6271,4601,7912,6281,7032,7222,474314124106391310
   > Long-term Assets 
7,446
6,741
6,037
5,318
4,565
4,810
3,154
2,508
1,851
1,020
349
233
188
146
114
69
165
137
636
1,193
6,386
5,719
3,367
4,096
9,060
8,781
8,7819,0604,0963,3675,7196,3861,193636137165691141461882333491,0201,8512,5083,1544,8104,5655,3186,0376,7417,446
       Property Plant Equipment 
94
116
141
147
120
249
222
332
431
357
322
215
179
146
114
69
165
137
169
707
2,389
2,603
2,700
2,851
7,720
7,127
7,1277,7202,8512,7002,6032,3897071691371656911414617921532235743133222224912014714111694
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
185
185
185
185
185
185
0
0
00185185185185185185000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
134
213
213134000000000000000000000000
       Intangible Assets 
7,352
6,624
5,896
5,171
4,445
4,561
2,932
2,176
1,420
663
28
18
9
0
0
0
0
0
0
185
185
185
185
185
185
185
185185185185185185185000000918286631,4202,1762,9324,5614,4455,1715,8966,6247,352
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
282
301
3,812
2,931
482
1,060
0
0
001,0604822,9313,812301282000000000000000000
> Total Liabilities 
124
318
211
535
1,392
2,601
3,082
2,433
3,156
4,563
3,081
3,757
2,358
1,976
1,726
2,439
2,304
3,163
3,489
5,166
7,873
9,830
18,390
29,082
28,112
30,941
30,94128,11229,08218,3909,8307,8735,1663,4893,1632,3042,4391,7261,9762,3583,7573,0814,5633,1562,4333,0822,6011,392535211318124
   > Total Current Liabilities 
124
318
211
535
1,370
2,577
3,067
2,428
3,147
4,544
3,040
3,717
2,339
1,946
1,718
2,435
2,288
3,148
3,471
4,960
6,660
8,707
13,732
25,495
25,212
27,211
27,21125,21225,49513,7328,7076,6604,9603,4713,1482,2882,4351,7181,9462,3393,7173,0404,5443,1472,4283,0672,5771,370535211318124
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
261
212
258
315
301
370
431
4313703013152582122610000000000000000000
       Accounts payable 
115
183
69
236
1,180
2,346
2,535
1,597
734
2,056
569
1,697
839
184
178
261
231
579
429
1,500
1,430
2,324
259
2,792
2,345
2,551
2,5512,3452,7922592,3241,4301,5004295792312611781848391,6975692,0567341,5972,5352,3461,18023669183115
       Other Current Liabilities 
9
135
141
300
191
231
532
831
2,413
2,488
2,471
2,020
1,500
1,762
1,540
2,175
2,057
2,568
3,042
3,199
5,018
6,125
5,878
6,308
6,646
24,229
24,2296,6466,3085,8786,1255,0183,1993,0422,5682,0572,1751,5401,7621,5002,0202,4712,4882,4138315322311913001411359
   > Long-term Liabilities 
0
0
0
0
22
24
15
5
9
19
41
40
19
29
8
3
15
15
18
205
1,213
1,123
4,658
3,588
2,900
3,731
3,7312,9003,5884,6581,1231,213205181515382919404119951524220000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8
3
15
15
18
34
106
78
3,717
2,889
0
0
002,8893,71778106341815153800000000000000
> Total Stockholder Equity
15,317
13,451
10,310
7,531
8,855
7,454
13,989
65,392
51,815
37,051
26,426
16,408
13,637
13,839
15,428
11,205
17,796
25,386
39,416
57,180
73,669
98,737
125,559
164,631
203,011
240,809
240,809203,011164,631125,55998,73773,66957,18039,41625,38617,79611,20515,42813,83913,63716,40826,42637,05151,81565,39213,9897,4548,8557,53110,31013,45115,317
   Common Stock
15,692
15,382
15,382
16,580
25,494
35,123
52,726
112,813
113,222
113,221
113,228
113,339
119,323
126,710
133,567
138,465
146,765
148,413
148,615
151,314
151,849
151,849
151,849
151,849
168,802
169,281
169,281168,802151,849151,849151,849151,849151,314148,615148,413146,765138,465133,567126,710119,323113,339113,228113,221113,222112,81352,72635,12325,49416,58015,38215,38215,692
   Retained Earnings 
-374
-1,932
-5,073
-9,050
-16,639
-27,668
-39,890
-49,066
-63,172
-78,337
-88,971
-100,145
-107,507
-114,122
-119,577
-129,958
-133,063
-125,847
-112,681
-95,487
-80,037
-58,130
-38,402
-9,774
29,964
63,632
63,63229,964-9,774-38,402-58,130-80,037-95,487-112,681-125,847-133,063-129,958-119,577-114,122-107,507-100,145-88,971-78,337-63,172-49,066-39,890-27,668-16,639-9,050-5,073-1,932-374
   Capital Surplus 00000000000000000000000000
   Treasury Stock00000000000000000000000000
   Other Stockholders Equity 
0
1
1
0
0
0
0
0
0
0
0
0
0
0
1,438
2,698
4,095
2,820
3,482
1,352
1,850
5,018
12,112
22,556
0
0
0022,55612,1125,0181,8501,3523,4822,8204,0952,6981,43800000000000110



6.3. Balance Sheets

Currency in AUD. All numbers in thousands.




6.4. Cash Flows

Currency in AUD. All numbers in thousands.




6.5. Income Statements

Currency in AUD. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2025-06-30. Currency in AUD. All numbers in thousands.

Gross Profit (+$)
totalRevenue95,018
Cost of Revenue-15,880
Gross Profit79,13779,137
 
Operating Income (+$)
Gross Profit79,137
Operating Expense-33,404
Operating Income45,73345,733
 
Operating Expense (+$)
Research Development-
Selling General Administrative26,854
Selling And Marketing Expenses-
Operating Expense33,40426,854
 
Net Interest Income (+$)
Interest Income9,431
Interest Expense-4,463
Other Finance Cost-0
Net Interest Income4,968
 
Pretax Income (+$)
Operating Income45,733
Net Interest Income4,968
Other Non-Operating Income Expenses-
Income Before Tax (EBT)51,55339,914
EBIT - interestExpense = 51,553
51,553
40,635
Interest Expense4,463
Earnings Before Interest and Taxes (EBIT)56,01656,016
Earnings Before Interest and Taxes (EBITDA)57,197
 
After tax Income (+$)
Income Before Tax51,553
Tax Provision-15,380
Net Income From Continuing Ops36,17336,173
Net Income36,173
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses49,284
Total Other Income/Expenses Net5,820-4,968
 

Technical Analysis of Clinuvel
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Clinuvel. The general trend of Clinuvel is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Clinuvel's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Clinuvel Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Clinuvel Pharmaceuticals Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 7.85 < 8.6 < 8.6.

The bearish price targets are: 6.81.

Know someone who trades $CLVLF? Share this with them.πŸ‘‡

Clinuvel Pharmaceuticals Ltd Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Clinuvel Pharmaceuticals Ltd. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Clinuvel Pharmaceuticals Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) ChartClinuvel Pharmaceuticals Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Clinuvel Pharmaceuticals Ltd. The current adx is .

Clinuvel Pharmaceuticals Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) ChartClinuvel Pharmaceuticals Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator ChartClinuvel Pharmaceuticals Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) ChartClinuvel Pharmaceuticals Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) ChartClinuvel Pharmaceuticals Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Williams %R ChartClinuvel Pharmaceuticals Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) ChartClinuvel Pharmaceuticals Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) ChartClinuvel Pharmaceuticals Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) ChartClinuvel Pharmaceuticals Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Clinuvel Pharmaceuticals Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-06-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-06-25MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-06-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-06-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-07-23STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-08-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-08-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-08-14RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-08-15STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-18STOCH SHORT EXITThe %K line crosses above the %D line.
2025-08-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-08-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-02STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-16CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-17MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-09-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-22WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-09-23MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-09-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-09-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-09-29SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-09-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-10-01STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-10-09STOCH LONG EXITThe %K line crosses below the %D line.
2025-10-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-10-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-10-20SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside

6.3. Candlestick Patterns

Clinuvel Pharmaceuticals Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Clinuvel Pharmaceuticals Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose7.430
Total0/1 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Clinuvel with someone you think should read this too:
  • Are you bullish or bearish on Clinuvel? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Clinuvel? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Clinuvel Pharmaceuticals Ltd

I send you an email if I find something interesting about Clinuvel Pharmaceuticals Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about Clinuvel Pharmaceuticals Ltd.

Receive notifications about Clinuvel Pharmaceuticals Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.